AVEO is committed to discovering, developing and commercializing targeted cancer therapies to impact patients’ lives. To support these efforts, we continue to evaluate opportunities to collaborate with other pharmaceutical and biotechnology companies that share AVEO’s vision for oncology drug development, and we seek partnerships that align with our strategic, long-term corporate goals.

AVEO has entered into multiple types of strategic partnership arrangements with several leading pharmaceutical and biotech companies:

EUSA Pharma

In December 2015, AVEO entered into an exclusive license agreement granting EUSA Pharma European rights to tivozanib for the treatment of advanced renal cell carcinoma (“RCC”). The agreement also includes a number of additional territories outside North America, including South America and South Africa, and additional potential indications.

Under the terms of the agreement, EUSA Pharma paid AVEO an upfront research and development funding payment of $2.5 million, and AVEO is eligible to receive up to $394 million in potential payments and milestones, assuming successful achievement of specified development, regulatory and commercialization objectives, as well as a tiered royalty ranging from a low double-digit up to mid-twenty percent on net sales of tivozanib in the agreement’s territories. A percentage of milestone and royalty payments received by AVEO are due to Kyowa Hakko Kirin as a sublicensing fee.

In September 2017, AVEO announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA® (tivozanib), opted into the Phase 1/2 TiNivo study and potential future combination development. Under terms of the agreement, EUSA may utilize data from the study for regulatory or commercial purposes in exchange for a research and development funding payment totaling $2.0 million.


In March 2016, AVEO granted CANbridge Life Sciences worldwide rights, excluding the United States, Canada, and Mexico, to AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate.

Under the terms of the collaboration and license agreement, CANbridge Life Sciences paid AVEO an upfront payment of $1 million and AVEO is eligible to receive up to $133 million in potential reimbursement and milestone payments, assuming the successful achievement of specified development, regulatory and commercialization objectives. AVEO is also eligible for a tiered royalty, with a percentage range in the low double digits, on net sales of AV-203 in the agreement’s territories.


In April 2014, AVEO entered into a worldwide agreement with Biodesix to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab.

Pursuant to this agreement Biodesix fully funded a study in NSCLC and will share 50% of all additional development, manufacturing and commercialization costs for the program. AVEO and Biodesix will equally share in any profits from the development of ficlatuzumab.

If you would like more information on current partnering opportunities with AVEO, we invite you to read more about our specific areas of interest or contact